Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Targeting FGG alleviates cholestatic fibrosis by inhibiting hepatic stellate cell activation and regulating macrophage homeostasis

Open access
Wei, Qianyi, Li, Minghao, Yang, Qiwei, Ren, Mengyao, Liu, Xudong, Cai, Xin, Shi, Jihua, Huang, Changjun, Wang, Yun, Zhang, Yi, Yu, Dongsheng, Guo, Wenzhi, Zhang, Shuijun · 2026 · Journal of Nanobiotechnology

Abstract

BACKGROUND & AIMS: Cholestatic liver injury is a serious pathological process with limited treatment options. The function of fibrinogen gamma chain (FGG) in the liver is not well defined. This study aims to explore the role of FGG in the progression of cholestatic liver fibrosis, and to find a new target for the treatment of cholestatic liver fibrosis. RESULTS: A BDL induced mouse model and LX2 cell line, as well as a co-culture system of LX2 and THP-1, were used. Gene expression, cell activation and polarization were evaluated by qRT-PCR, Western Blot, RNA-seq, and immunofluorescence. 4-Octyl itaconate (OI) was used to block the M2 polarization, and an AEAA-modified lipid nanoparticle (LNP) was developed as a platform for targeted delivery of siFGG, and its therapeutic efficacy was evaluated in vitro and in vivo. In the BDL mouse, FGG expression was significantly increased and mainly localized to activated hepatic stellate cells (HSCs). In vitro experiments confirmed that FGG directly regulated the activation state of HSCs. Overexpression of FGG in mice significantly promoted the development of liver fibrosis. Further studies revealed that FGG specifically promoted macrophage polarization toward the M2 phenotype. Co-culture experiments demonstrated that FGG was a key factor driving M2 polarization of macrophages. The siFGG delivered by AEAA-LNP effectively knocked down the expression of FGG, thereby inhibiting HSC activation, disrupting the crosstalk between HSC and M2 macrophages, and ultimately significantly alleviating BDL induced liver fibrosis in vitro and in vivo. CONCLUSIONS: This study identifies FGG as a key fibrosis promoter that acts through simultaneous HSC activation and M2 macrophage polarization. Targeting FGG with a novel AEAA-LNP system offers a potent dual-mechanism therapy for liver fibrosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12951-026-04432-z

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Figures

FGG functions as a critical molecule in cholestatic liver fibrosis by driving HSCs activation and facilitating M2 macrophage polarization
FGG functions as a critical molecule in cholestatic liver fibrosis by driving HSCs activation and facilitating M2 macrophage polarizationCC BY-NC-ND · PubMed Central
Fig. 1 FGG functions as a critical molecule in cholestatic liver fibrosis by driving HSCs activation and facilitating M2 macrophage polarization. During cholestasis, accumulated bile acids induce HSCs activation, leading to a substantial increase in FGG secretion. The released FGG not only further sustains HSC activation in an autocrine manner but also acts as a key paracrine signal to polarize macrophages toward an M2 phenotype. This FGG-mediated communication establishes a vicious cycle where in M2 macrophages and activated HSCs engage in reciprocal crosstalk, collectively accelerating fibrotic progression. To therapeutically target this pathway, we developed AEAA@LNP-siFGG, a targeted delivery system that markedly enhances siRNA uptake in HSCs. Treatment with this system efficiently knocked down FGG expression, resulting in suppressed HSCs activation, disrupted profibrotic HSC and macrophage crosstalk, and ultimately significant attenuation of liver fibrosis
Fig. 1 FGG functions as a critical molecule in cholestatic liver fibrosis by driving HSCs activation and facilitating M2 macrophage polarization. During cholestasis, accumulated bile acids induce HSCs activation, leading to a substantial increase in FGG secretion. The released FGG not only further sustains HSC activation in an autocrine manner but also acts as a key paracrine signal to polarize macrophages toward an M2 phenotype. This FGG-mediated communication establishes a vicious cycle where in M2 macrophages and activated HSCs engage in reciprocal crosstalk, collectively accelerating fibrotic progression. To therapeutically target this pathway, we developed AEAA@LNP-siFGG, a targeted delivery system that markedly enhances siRNA uptake in HSCs. Treatment with this system efficiently knocked down FGG expression, resulting in suppressed HSCs activation, disrupted profibrotic HSC and macrophage crosstalk, and ultimately significant attenuation of liver fibrosisCC BY-NC-ND · PubMed Central
Fig. 2 FGG is increased in BDL induced liver injury. (A-B) TBIL and DBIL levels after BDL7d and BDL14d (n = 5). (C-F) γ-GT, AST, ALT and AKP levels after BDL7d and BDL14d (n = 5). (G) H&E, Sirius red, IHC of α-SMA and Col1a1 of liver tissue (n = 5) sections were performed to assess collagen deposition and fibrosis severity. Representative images from the sham, BDL7d and BDL14d groups are shown. (H) Volcano plots showing differential gene expression between the BDL7d model vs. control. Upregulated genes are shown in red, downregulated genes in blue and FGG in green. (I) Volcano plots showing differential gene expression from GSE166752 datasets between the BDL15d model vs. control. Upregulated genes are shown in red, downregulated genes in blue and FGG in green. (J) IHC of FGG after BDL7d and BDL14d. (K) WB of FGG, α-SMA, Col1a1 and GAPDH after BDL7d and BDL14d. (L) Corresponding quantitative of FGG, α-SMA and Col1a1 in liver after BDL (n = 5). (M) mRNA levels of FGG, α-SMA and Col1a1 in liver after BDL (n = 5). (N) IF of FGG and α-SMA in liver after BDL. (O) Corresponding quantitative of FGG and α-SMA after BDL7d. (P) Corresponding quantitative of FGG and α-SMA after BDL14d. Data were presented as the mean ± SD, *P < 0.05, **P < 0.01, P < 0.001, ****P < 0.0001
Fig. 2 FGG is increased in BDL induced liver injury. (A-B) TBIL and DBIL levels after BDL7d and BDL14d (n = 5). (C-F) γ-GT, AST, ALT and AKP levels after BDL7d and BDL14d (n = 5). (G) H&E, Sirius red, IHC of α-SMA and Col1a1 of liver tissue (n = 5) sections were performed to assess collagen deposition and fibrosis severity. Representative images from the sham, BDL7d and BDL14d groups are shown. (H) Volcano plots showing differential gene expression between the BDL7d model vs. control. Upregulated genes are shown in red, downregulated genes in blue and FGG in green. (I) Volcano plots showing differential gene expression from GSE166752 datasets between the BDL15d model vs. control. Upregulated genes are shown in red, downregulated genes in blue and FGG in green. (J) IHC of FGG after BDL7d and BDL14d. (K) WB of FGG, α-SMA, Col1a1 and GAPDH after BDL7d and BDL14d. (L) Corresponding quantitative of FGG, α-SMA and Col1a1 in liver after BDL (n = 5). (M) mRNA levels of FGG, α-SMA and Col1a1 in liver after BDL (n = 5). (N) IF of FGG and α-SMA in liver after BDL. (O) Corresponding quantitative of FGG and α-SMA after BDL7d. (P) Corresponding quantitative of FGG and α-SMA after BDL14d. Data were presented as the mean ± SD, *P < 0.05, **P < 0.01, P < 0.001, ****P < 0.0001CC BY-NC-ND · PubMed Central
Fig. 3 FGG potentiates the activation of hepatic stellate cells. (A) mRNA levels of FGG, α-SMA and Col1a1 in LX2 stimulated by different concentrations of TGF-β (n = 3). (B) Corresponding quantitative of FGG, α-SMA and Col1a1 proteins in LX2 stimulated by different concentrations of TGF-β (n = 3). (C) WB of FGG, α-SMA, Col1a1 and GAPDH in LX2 stimulated by different concentrations of TGF-β. (D) IF of FGG in LX2 and activated LX2. (E) Quantitative analysis of FGG in LX2 and activated LX2 (n = 3). (F) mRNA levels of FGG, α-SMA and Col1a1 in LX2 with FGG overexpression in different treated (n = 3). (G) WB of FGG, α-SMA and Col1a1 in LX2 with FGG overexpression in different treated. (H) Corresponding quantitative of FGG, α-SMA and Col1a1 in LX2 with FGG overexpression in different treated (n = 3). (I) IF of α-SMA in LX2 with FGG overexpression in different treated. (J) mRNA levels of FGG, α-SMA and Col1a1 in LX2 with siFGG in different treated (n = 3). (K) WB of FGG, α-SMA and Col1a1 in LX2 with siFGG in different treated. (L) Corresponding quantitative of FGG, α-SMA and Col1a1 in LX2 with siFGG in different treated (n = 3). (M) IF of α-SMA in LX2 with siFGG in different treated. Ctrl, quiescent LX2. Ctrl + TGF-β, activated LX2. OE, overexpressing FGG in quiescent LX2. OE + TGF-β, overexpressing FGG in activated LX2. siFGG, knockdown FGG in quiescent LX2. siFGG + TGF-β, knockdown FGG in activated LX2. Data were presented as the mean ± SD, *P < 0.05, **P < 0.01, P < 0.001, ****P < 0.0001
Fig. 3 FGG potentiates the activation of hepatic stellate cells. (A) mRNA levels of FGG, α-SMA and Col1a1 in LX2 stimulated by different concentrations of TGF-β (n = 3). (B) Corresponding quantitative of FGG, α-SMA and Col1a1 proteins in LX2 stimulated by different concentrations of TGF-β (n = 3). (C) WB of FGG, α-SMA, Col1a1 and GAPDH in LX2 stimulated by different concentrations of TGF-β. (D) IF of FGG in LX2 and activated LX2. (E) Quantitative analysis of FGG in LX2 and activated LX2 (n = 3). (F) mRNA levels of FGG, α-SMA and Col1a1 in LX2 with FGG overexpression in different treated (n = 3). (G) WB of FGG, α-SMA and Col1a1 in LX2 with FGG overexpression in different treated. (H) Corresponding quantitative of FGG, α-SMA and Col1a1 in LX2 with FGG overexpression in different treated (n = 3). (I) IF of α-SMA in LX2 with FGG overexpression in different treated. (J) mRNA levels of FGG, α-SMA and Col1a1 in LX2 with siFGG in different treated (n = 3). (K) WB of FGG, α-SMA and Col1a1 in LX2 with siFGG in different treated. (L) Corresponding quantitative of FGG, α-SMA and Col1a1 in LX2 with siFGG in different treated (n = 3). (M) IF of α-SMA in LX2 with siFGG in different treated. Ctrl, quiescent LX2. Ctrl + TGF-β, activated LX2. OE, overexpressing FGG in quiescent LX2. OE + TGF-β, overexpressing FGG in activated LX2. siFGG, knockdown FGG in quiescent LX2. siFGG + TGF-β, knockdown FGG in activated LX2. Data were presented as the mean ± SD, *P < 0.05, **P < 0.01, P < 0.001, ****P < 0.0001CC BY-NC-ND · PubMed Central
Fig. 4 FGG promotes liver fibrosis and inflammation. (A) WB of FGG, α-SMA and Col1a1 in liver with FGG knockdown in different group (n = 5). (B-G) ALT, AST, γ-GT, AKP, TBIL and DBIL levels with FGG knockdown in different group (n = 5). (H) H&E, Sirius red, IF of α-SMA and Col1a1 of liver tissue (n = 5) sections were performed to assess collagen deposition and fibrosis severity. (I) Boxplot of normalized RNA-seq data showing uniform distribution across samples. (J) PCA plot between BDL and shFGG + BDL groups. (K) GO enrichment analysis of differentially expressed genes (DEGs). (L) KEGG enrichment analysis of upregulated DEGs. (M) and (N) Western blot analysis and corresponding quantification of Arg-1, and PI3K/AKT pathway-related proteins (p-mTOR, mTOR, p-AKT, AKT) in liver tissue (n = 5). (O) and (P) IF and statistical analysis of F4/80, CD206 and CD86 in liver tissue (n = 5). shNC, tail vein injection of non-targeting AAV. shNC + BDL, the same AAV injection as the shNC group followed by BDL. shFGG, tail vein injection of FGG-targeting AAV. shFGG + BDL, the same AAV injection as the shFGG group followed by BDL. Data were presented as the mean ± SD, *P < 0.05, **P < 0.01, P < 0.001, ****P < 0.0001
Fig. 4 FGG promotes liver fibrosis and inflammation. (A) WB of FGG, α-SMA and Col1a1 in liver with FGG knockdown in different group (n = 5). (B-G) ALT, AST, γ-GT, AKP, TBIL and DBIL levels with FGG knockdown in different group (n = 5). (H) H&E, Sirius red, IF of α-SMA and Col1a1 of liver tissue (n = 5) sections were performed to assess collagen deposition and fibrosis severity. (I) Boxplot of normalized RNA-seq data showing uniform distribution across samples. (J) PCA plot between BDL and shFGG + BDL groups. (K) GO enrichment analysis of differentially expressed genes (DEGs). (L) KEGG enrichment analysis of upregulated DEGs. (M) and (N) Western blot analysis and corresponding quantification of Arg-1, and PI3K/AKT pathway-related proteins (p-mTOR, mTOR, p-AKT, AKT) in liver tissue (n = 5). (O) and (P) IF and statistical analysis of F4/80, CD206 and CD86 in liver tissue (n = 5). shNC, tail vein injection of non-targeting AAV. shNC + BDL, the same AAV injection as the shNC group followed by BDL. shFGG, tail vein injection of FGG-targeting AAV. shFGG + BDL, the same AAV injection as the shFGG group followed by BDL. Data were presented as the mean ± SD, *P < 0.05, **P < 0.01, P < 0.001, ****P < 0.0001CC BY-NC-ND · PubMed Central
Fig. 5 FGG promote M2 macrophage polarization in vitro. (A-B) and (K-L) Immunofluorescence staining of Arg-1 (green) and iNOS (red) in THP-1 cells observed by confocal microscopy. (C) and (E) Flow cytometric analysis of M1 marker CD86 and M2 marker CD206 expression. (D) and (F) Quantification of flow cytometric analysis (n = 3). (G) and (H) Western blot analysis and corresponding quantification of Arg-1, and PI3K/AKT/mTOR pathway-related proteins (p-mTOR, mTOR, p-AKT, AKT) in THP-1 cells with different treatments (n = 3). (I) and (J) Morphological analysis of THP-1 cells with different treatments (n = 3). Ctrl, THP-1. LX2, THP-1 with CM1. Vector, THP-1 with CM2. OE, THP-1 with CM3. si, THP-1 with CM4. si + FGG, THP-1 with CM4 added FGG purified protein. Data were presented as the mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001
Fig. 5 FGG promote M2 macrophage polarization in vitro. (A-B) and (K-L) Immunofluorescence staining of Arg-1 (green) and iNOS (red) in THP-1 cells observed by confocal microscopy. (C) and (E) Flow cytometric analysis of M1 marker CD86 and M2 marker CD206 expression. (D) and (F) Quantification of flow cytometric analysis (n = 3). (G) and (H) Western blot analysis and corresponding quantification of Arg-1, and PI3K/AKT/mTOR pathway-related proteins (p-mTOR, mTOR, p-AKT, AKT) in THP-1 cells with different treatments (n = 3). (I) and (J) Morphological analysis of THP-1 cells with different treatments (n = 3). Ctrl, THP-1. LX2, THP-1 with CM1. Vector, THP-1 with CM2. OE, THP-1 with CM3. si, THP-1 with CM4. si + FGG, THP-1 with CM4 added FGG purified protein. Data were presented as the mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001CC BY-NC-ND · PubMed Central
Fig. 6 FGG Promotes Liver Fibrosis via Macrophage M2 Polarization in vitro. (A-B) Western blot analysis and corresponding quantification of ATF6/TGF-β/SMAD3 pathway-related proteins in THP-1 cells with different treatments. (C-E) Western blot analysis and corresponding quantification of Arg-1 and p-SMAD3 in THP-1 cells with different treatments (n = 3). (F-I) Western blot analysis of Arg-1, CD86, CD206 in THP-1 cells with different treatments and Corresponding quantification of Arg-1 in THP-1 cells with different treatments (n = 3). (J-K) IF of α-SMA in LX2 cells with different treatments and quantification of IF in LX2 (n = 3). (L-M) Flow cytometric analysis and corresponding quantification of M1 marker CD86 and M2 marker CD206 expression (n = 3). (N-O) Western blot analysis and corresponding quantification of α-SMA and Col1a1 in LX2 cells (n = 3). (P) Microscopic images of migrated LX2. All data were presented as the mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001
Fig. 6 FGG Promotes Liver Fibrosis via Macrophage M2 Polarization in vitro. (A-B) Western blot analysis and corresponding quantification of ATF6/TGF-β/SMAD3 pathway-related proteins in THP-1 cells with different treatments. (C-E) Western blot analysis and corresponding quantification of Arg-1 and p-SMAD3 in THP-1 cells with different treatments (n = 3). (F-I) Western blot analysis of Arg-1, CD86, CD206 in THP-1 cells with different treatments and Corresponding quantification of Arg-1 in THP-1 cells with different treatments (n = 3). (J-K) IF of α-SMA in LX2 cells with different treatments and quantification of IF in LX2 (n = 3). (L-M) Flow cytometric analysis and corresponding quantification of M1 marker CD86 and M2 marker CD206 expression (n = 3). (N-O) Western blot analysis and corresponding quantification of α-SMA and Col1a1 in LX2 cells (n = 3). (P) Microscopic images of migrated LX2. All data were presented as the mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001CC BY-NC-ND · PubMed Central
Fig. 7 FGG Promotes Liver Fibrosis via Macrophage M2 Polarization in vivo. (A) H&E, Sirius red, Masson, IF of α-SMA and Col1a1 of liver tissue (n = 5) sections were performed to assess collagen deposition and fibrosis severity. (B) Quantification of Sirius red and Masson (n = 5). (C) Quantification of α-SMA and Col1a1. (D) IF and statistical analysis of F4/80, CD206 and CD86 in liver tissue (n = 5). (E) Quantification of F4/80, CD206 and CD86 (n = 5). (F-G) Western blot analysis and corresponding quantification of Arg-1, iNOS, α-SMA and Col1a1 in liver tissue with different treatments (n = 5). Data were presented as the mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001
Fig. 7 FGG Promotes Liver Fibrosis via Macrophage M2 Polarization in vivo. (A) H&E, Sirius red, Masson, IF of α-SMA and Col1a1 of liver tissue (n = 5) sections were performed to assess collagen deposition and fibrosis severity. (B) Quantification of Sirius red and Masson (n = 5). (C) Quantification of α-SMA and Col1a1. (D) IF and statistical analysis of F4/80, CD206 and CD86 in liver tissue (n = 5). (E) Quantification of F4/80, CD206 and CD86 (n = 5). (F-G) Western blot analysis and corresponding quantification of Arg-1, iNOS, α-SMA and Col1a1 in liver tissue with different treatments (n = 5). Data were presented as the mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001CC BY-NC-ND · PubMed Central
Fig. 8 Synthesis and knockdown efficiency of liposomes. (A) TEM image of AEAA@LNP-siFGG. (B) The polydispersity index and (C) zeta potential of LNPs-based gene delivery systems was determined via dynamic light scattering. (D) The loading capacity of LNPs for siRNA was determined via agarose gel electrophoresis. (E) Average particle size of AEAA@LNP-siFGG over 7 days. (F) Variation in zeta potential of AEAA@LNP-siFGG over 7 days. (G) Variation in PDI of AEAA@LNP-siFGG over 7 days. (H-I) Uptake efficiency and quantification of different liposomes by mouse primary hepatic stellate cells and (J-K) Time-dependent efficiency and quantification of liposome uptake by mouse primary hepatic stellate cells. (L-M) Protein levels and corresponding quantification of FGG, α-SMA and Col1a1 in mouse primary HSCs treated with various LNPs. (N-O) and (P-Q) Immunofluorescence staining of FGG (yellow) and α-SMA (red) in mouse primary HSCs observed by confocal microscopy. (O) and (Q) Quantitative analysis of ((N) and (P)) (n = 3). LNP, empty LNPs. LNP-siFGG, LNPs encapsulating FGG-targeting siRNA. AEAA@LNP-siFGG, AEAA-modified LNPs encapsulating FGG-targeting siRNA. Data were presented as the mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001
Fig. 8 Synthesis and knockdown efficiency of liposomes. (A) TEM image of AEAA@LNP-siFGG. (B) The polydispersity index and (C) zeta potential of LNPs-based gene delivery systems was determined via dynamic light scattering. (D) The loading capacity of LNPs for siRNA was determined via agarose gel electrophoresis. (E) Average particle size of AEAA@LNP-siFGG over 7 days. (F) Variation in zeta potential of AEAA@LNP-siFGG over 7 days. (G) Variation in PDI of AEAA@LNP-siFGG over 7 days. (H-I) Uptake efficiency and quantification of different liposomes by mouse primary hepatic stellate cells and (J-K) Time-dependent efficiency and quantification of liposome uptake by mouse primary hepatic stellate cells. (L-M) Protein levels and corresponding quantification of FGG, α-SMA and Col1a1 in mouse primary HSCs treated with various LNPs. (N-O) and (P-Q) Immunofluorescence staining of FGG (yellow) and α-SMA (red) in mouse primary HSCs observed by confocal microscopy. (O) and (Q) Quantitative analysis of ((N) and (P)) (n = 3). LNP, empty LNPs. LNP-siFGG, LNPs encapsulating FGG-targeting siRNA. AEAA@LNP-siFGG, AEAA-modified LNPs encapsulating FGG-targeting siRNA. Data were presented as the mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001CC BY-NC-ND · PubMed Central
Fig. 9 Therapeutic Attenuation of Liver Fibrosis Through Targeted FGG Silencing via AEAA@LNP-siFGG. (A-B) Western blot analysis and corresponding quantification of Arg-1, iNOS and CD86 in RAW264.7 cells. (C) IF of Arg-1 in RAW264.7 cells. (D) Western blot analysis of ATF6/TGF-β/SMAD3 pathway-related proteins in RAW264.7 cells. (E) Quantitative analysis of (D). (F) Microscopic images of migrated in mouse primary HSCs. (G) H&E, Sirius red, Masson, IF of α-SMA and Col1a1 of liver tissue (n = 5) sections were performed to assess collagen deposition and fibrosis severity. (H) Quantification of Sirius red, α-SMA and Col1a1(n = 5). (I) IF of F4/80, CD206 and CD86 in liver tissue. (J) Quantification of F4/80 and CD206 in liver tissue (n = 5). mHSC, co-culture with mHSC. LNP, empty LNPs. LNP-siNC, LNPs encapsulating non-targeting siRNA. LNP-siFGG, LNPs encapsulating FGG-targeting siRNA. AEAA@LNP-siRNA, AEAA-modified LNPs encapsulating FGG-targeting siRNA. Data were presented as the mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001
Fig. 9 Therapeutic Attenuation of Liver Fibrosis Through Targeted FGG Silencing via AEAA@LNP-siFGG. (A-B) Western blot analysis and corresponding quantification of Arg-1, iNOS and CD86 in RAW264.7 cells. (C) IF of Arg-1 in RAW264.7 cells. (D) Western blot analysis of ATF6/TGF-β/SMAD3 pathway-related proteins in RAW264.7 cells. (E) Quantitative analysis of (D). (F) Microscopic images of migrated in mouse primary HSCs. (G) H&E, Sirius red, Masson, IF of α-SMA and Col1a1 of liver tissue (n = 5) sections were performed to assess collagen deposition and fibrosis severity. (H) Quantification of Sirius red, α-SMA and Col1a1(n = 5). (I) IF of F4/80, CD206 and CD86 in liver tissue. (J) Quantification of F4/80 and CD206 in liver tissue (n = 5). mHSC, co-culture with mHSC. LNP, empty LNPs. LNP-siNC, LNPs encapsulating non-targeting siRNA. LNP-siFGG, LNPs encapsulating FGG-targeting siRNA. AEAA@LNP-siRNA, AEAA-modified LNPs encapsulating FGG-targeting siRNA. Data were presented as the mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Cited by

Still being checked.

Metadata

Authors
Wei, Q., Li, M., Yang, Q., Ren, M., Liu, X., Cai, X., Shi, J., Huang, C., Wang, Y., Zhang, Y., Yu, D., Guo, W., & Zhang, S.
Affiliations
  • First Affiliated Hospital of Zhengzhou University (CN)
  • Xuzhou Central Hospital (CN)
Corresponding author
  • Yu, Dongsheng
  • Guo, Wenzhi
  • Zhang, Shuijun
Venue
Journal of Nanobiotechnology
Published
2026-04-18
Volume
24
Issue
1
ISSN
1477-3155 (ISSN-L)
OpenAlex
W7154844307
Cited by
0
References
51
FWCI
0.00
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Nanobiotechnology (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • New Round of Xuzhou "Pengcheng Talent Program"-High-level Healthcare Talent Recruitment and Development Project (2025QZ004)
  • National Natural Science Foundation of China (82170670)
  • Medical Science and Technology Program of Henan (SB201901045)
Topics
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Keywords
fibrinogen gamma chain, cholestatic liver fibrosis, hepatic stellate cell activation, M2 macrophage polarization, hepatic macrophages, bile duct ligation, siRNA delivery, lipid nanoparticles
MeSH terms
Animals, Cell Line, Cholestasis, Disease Models, Animal, Homeostasis, Humans, Liver Cirrhosis, Macrophages, Male, Mice, Inbred C57BL, Coculture Techniques, Mice, Hepatic Stellate Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting FGG alleviates cholestatic fibrosis by inhibiting hepatic stellate cell activation and regulating macrophage homeostasis. https://app.cochat.ai/papers/10.1186/s12951-026-04432-z
The paper
Wei, Q., Li, M., Yang, Q., Ren, M., Liu, X., Cai, X., Shi, J., Huang, C., Wang, Y., Zhang, Y., Yu, D., Guo, W., & Zhang, S. (2026). Targeting FGG alleviates cholestatic fibrosis by inhibiting hepatic stellate cell activation and regulating macrophage homeostasis. Journal of Nanobiotechnology. https://doi.org/10.1186/s12951-026-04432-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.